Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

November 24, 2022

View Archives Issues

  • Oral Vitamin K for Excessive Anticoagulation

    Whether oral vitamin K reduces the risk of bleeding related to excessive anticoagulation from warfarin remains unclear.
  • Azacitidine for High-risk MDS

    In an international, multi-center trial of azacitidine in patients with either intermediate-2 or high-risk MDS, overall survival was significantly increased when compared to conventional therapy, which at the discretion of the investigator and patient, could have included intense chemotherapy, low-dose cytarabine, or best supportive care.
  • Weekly Dose-dense Paclitaxel-Carboplatin for Recurrent Ovarian Cancer

    Using a "dose-dense" regimen of paclitaxel and carboplatin in heavily pre-treated, platinum- resistant ovarian cancer patients, a UK oncology group demonstrated that a more protracted treatment schedule (six months) was both tolerable and associated with an impressive overall response rate (60%). The findings provide rationale for a randomized clinical trial to examine this approach for relapsed ovarian cancer, particularly for those who relapse within a year of completing initial platinum-based treatment.
  • Breast Cancer During Pregnancy

    Of 688 breast cancers occurring in 652 women 35 years and younger, 15.6% were associated with pregnancy (either during pregnancy or during the subsequent year). Although the tumors occurring in association with pregnancy were larger, there was no significant difference in local recurrence, distant metastases, or overall survival.
  • Combined Endocrine and Radiation Approach for Locally Advanced Prostate Cancer

    In patients with advanced- or high-risk but local prostate cancer, the addition of local radiotherapy to endocrine treatment was shown to halve the 10-year prostate cancer-specific mortality and substantially reduce overall mortality in a phase III, randomized, multi-center clinical trial conducted in Northern Europe.
  • Clinical Briefs in Primary Care Supplement

  • Pharmacology Watch

    Individualizatÿ